Experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT)

Background: This study aims to provide evidence of factors that impact participant reported serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT). Methods: Data from an 18-month longitudinal retrospective cohort of individuals receiving iOAT wa...

Full description

Bibliographic Details
Published in:	Journal of Affective Disorders Reports
Main Authors:	Tianna Magel, Ying C MacNab, Scott MacDonald, Eugenia Oviedo-Joekes
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Subjects:	Depression Anxiety Injectable opioid agonist treatment Opioid use disorder Person-centered care
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666915323002329

Similar Items

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)
by: Scott Beaumont, et al.
Published: (2024-01-01)

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study
by: Dobischok S, et al.
Published: (2022-12-01)

Changes in daily dose in open-label compared to double-blind: The role of clients’ expectations in injectable opioid agonist treatment
by: Sarin Blawatt, et al.
Published: (2023-06-01)

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
by: Alison Adams, et al.
Published: (2023-09-01)

“As long as that place stays open, I’ll stay alive”: Accessing injectable opioid agonist treatment during dual public health crises
by: Kaitlyn Jaffe, et al.
Published: (2023-04-01)

First-line opioid agonist treatment as prevention against assisting others in initiating injection drug use: A longitudinal cohort study of people who inject drugs in Vancouver, Canada
by: Zachary Bouck, et al.
Published: (2023-06-01)

Opioid analgesics for chronic noncancer pain in patients prescribed opioid agonist therapy or with opioid use disorder: A systematic review
by: Vahid Ashoorion, et al.
Published: (2025-12-01)

Prevalence of alcohol consumption among clients of opioid agonist treatment (OAT) centers in Golestan province, Iran
by: Alireza Noroozi, et al.
Published: (2023-05-01)

Gender differences regarding interest in opioid agonist treatment with hydromorphone: a cross-sectional study of syringe service program participants
by: Vitaliy Lasiychuk, et al.
Published: (2025-08-01)

Safety and Efficacy of Combined Injection of Pure-μ-Opioid Agonist with Tramadol as an Opioid Induction Agent for Opioid-Naïve Cancer Patients
by: Tetsumi Sato, et al.
Published: (2024-10-01)

Oral and injectable opioid agonist treatments for people who use street opioids: a systematic literature review and network meta-analysis
by: Nick Bansback, et al.
Published: (2025-08-01)

Psychiatrist-led treatment of hepatitis C (HCV) at an opioid agonist treatment (OAT) clinic in Stockholm - enhancing the HCV treatment care cascade
by: M. Kåberg, et al.
Published: (2022-06-01)

Practitioner perspectives on working with older patients in opioid agonist treatment (OAT) in Norway: opportunities and challenges
by: John Todd-Kvam, et al.
Published: (2024-05-01)

The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: findings from the OATS retrospective linkage study.
by: Nicola Jones, et al.
Published: (2022-08-01)

<it>In vivo </it>antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera
by: Guillemyn Karel, et al.
Published: (2012-01-01)

Prevalence of COVID-19 outcomes in patients referred to opioid agonist treatment centers
by: Samira Khani, et al.
Published: (2023-03-01)

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
by: Heather Palis, et al.
Published: (2021-05-01)

Agonists Specific for κ-Opioid Receptor Induces Apoptosis of HCC Cells Through Enhanced Endoplasmic Reticulum Stress
by: Mengyuan Tan, et al.
Published: (2022-03-01)

Challenges for the implementation of injectable opioid agonist treatment: a scoping review
by: Tanja Schwarz, et al.
Published: (2024-12-01)

Erratum: Agonists Specific for κ-Opioid Receptor Induces Apoptosis of HCC Cells Through Enhanced Endoplasmic Reticulum Stress
by: Frontiers Production Office
Published: (2022-05-01)

NOP agonist AT-403 promoted sleep in lactic acid-induced acute pain model
by: Bethany E. Pierce, et al.
Published: (2025-09-01)

Role for μ-opioid receptor in antidepressant effects of δ-opioid receptor agonist KNT-127
by: Yuki Moriya, et al.
Published: (2023-03-01)

Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada
by: Cayley Russell, et al.
Published: (2022-12-01)

Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study
by: Anne Bouthillier, et al.
Published: (2025-02-01)

Clinical Outcomes of Benzodiazepine Prescribing for People Receiving Opioid Agonist Treatment: A Systematic Review of the Evidence
by: Catriona Matheson, et al.
Published: (2024-10-01)

Care cascade for patients with opioid use disorder and serious injection related infections
by: Anand Upadhyaya, et al.
Published: (2021-11-01)

Measuring sustainability of opioid agonist therapy programs in the context of transition from Global Fund support
by: Raminta Stuikyte, et al.
Published: (2024-01-01)

Neurocognitive performance of patients undergoing intravenous versus oral opioid agonist treatment: a prospective multicenter study on three-month treatment effects
by: Sunsha Chamakalayil, et al.
Published: (2024-07-01)

Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system
by: Guido Mannaioni, et al.
Published: (2023-01-01)

A Case report of a continuous ambulatory drug delivery (CADD) pump to deliver opioid agonist treatment in an acute care setting
by: Casey Wigg, et al.
Published: (2023-09-01)

Harnessing the Anti-Nociceptive Potential of NK2 and NK3 Ligands in the Design of New Multifunctional μ/δ-Opioid Agonist–Neurokinin Antagonist Peptidomimetics
by: Charlène Gadais, et al.
Published: (2021-09-01)

Corrigendum: Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system
by: Guido Mannaioni, et al.
Published: (2023-12-01)

Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment
by: Marchand Kirsten, et al.
Published: (2012-01-01)

Evaluating the Impact of Increased Dispensing of Opioid Agonist Therapy Take-Home Doses on Treatment Retention and Opioid-Related Harm among Opioid Agonist Therapy Recipients: A Simulation Study
by: Narjes Shojaati, et al.
Published: (2023-08-01)

The potential use of digital technologies to enhance opioid agonist treatment in rural and remote communities of British Columbia, Canada
by: Amreetha Jayathilake, et al.
Published: (2025-10-01)

Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada
by: Samara Mayer, et al.
Published: (2025-07-01)

Pain Intensity in Patients with Opioid Use Disorder on Extended-Release Naltrexone or Opioid Agonists; The Role of COMT rs4680 and OPRM1 rs1799971: An Exploratory Study
by: Juya F, et al.
Published: (2025-02-01)

An emergency-department-initiated outreach program for patients with opioid use disorder is associated with an increase in agonist therapy and engagement in addictions care: a one-year cohort study
by: Rukaiyah Lakkadghatwala, et al.
Published: (2024-02-01)

The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC
by: Dobischok S, et al.
Published: (2023-11-01)

Impact of hepatitis C serostatus on health service utilization for opioid-related harms among individuals prescribed opioid agonist therapy: A longitudinal prospective cohort study
by: Paige Guyatt, et al.
Published: (2025-09-01)